Screening of Peptides Bound to Breast Cancer Stem Cell Specific Surface Marker CD44 by Phage Display

被引:0
|
作者
Hye-Yeon Park
Kyoung-Jin Lee
Su-Jae Lee
Moon-Young Yoon
机构
[1] Hanyang University,Department of Chemistry, College of Natural Sciences
来源
Molecular Biotechnology | 2012年 / 51卷
关键词
Breast cancer; Cancer stem cell marker; Diagnostics probe; CD44-binding peptides; M13 phage display;
D O I
暂无
中图分类号
学科分类号
摘要
CD44, a cancer-associated membrane glycoprotein involved in cell adhesion and tumor progression, has been implicated as a cancer stem cell antigen in several cancers including breast cancer. If the detection sensitivity of CD44 as an early marker for cancer could be improved, this would have important clinical applications. As compared with early stage treatments of other kinds of cancer, treatment of breast cancer is more likely to results in positive outcomes, so this early detection is crucial. Therefore, CD44 is a potential diagnostic target for cancer detection. Herein, we have used a peptide library to screen novel diverse peptides that bind to CD44 with high affinity and characterized the specific binding of these peptides. Our work provides a basis to develop novel diagnostic peptides which may replace antibodies as CD44 detection probes.
引用
收藏
页码:212 / 220
页数:8
相关论文
共 50 条
  • [21] Prognostic role of the cancer stem cell marker CD44 in ovarian cancer: a meta-analysis
    Shi, Y. Y.
    Jiang, H.
    GENETICS AND MOLECULAR RESEARCH, 2016, 15 (03)
  • [22] In Vitro Selection of Modified RNA Aptamers Against CD44 Cancer Stem Cell Marker
    Ababneh, Nidaa
    Alshaer, Walhan
    Allozi, Omar
    Mahafzah, Azmi
    El-Khateeb, Mohammed
    Hillaireau, Herve
    Noiray, Magali
    Fattal, Elias
    Ismail, Said
    NUCLEIC ACID THERAPEUTICS, 2013, 23 (06) : 401 - 407
  • [23] NEAT1 is Required for the Expression of the Liver Cancer Stem Cell Marker CD44
    Koyama, Shigemi
    Tsuchiya, Hiroyuki
    Amisaki, Masataka
    Sakaguchi, Hiromi
    Honjo, Soichiro
    Fujiwara, Yoshiyuki
    Shiota, Goshi
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (06)
  • [24] Effect of curcumin on the cell surface markers CD44 and CD24 in breast cancer
    Calaf, Gloria M.
    Ponce-Cusi, Richard
    Abarca-Quinones, Jorge
    ONCOLOGY REPORTS, 2018, 39 (06) : 2741 - 2748
  • [25] CD44 splice isoform switching determines breast cancer stem cell state
    Zhang, Honghong
    Brown, Rhonda L.
    Wei, Yong
    Zhao, Pu
    Liu, Sali
    Liu, Xuan
    Deng, Yu
    Hu, Xiaohui
    Zhang, Jing
    Gao, Xin D.
    Kang, Yibin
    Mercurio, Arthur M.
    Goel, Hira Lal
    Cheng, Chonghui
    GENES & DEVELOPMENT, 2019, 33 (3-4) : 166 - 179
  • [26] CD44 as a cancer stem cell marker and its prognostic value in patients with ovarian carcinoma
    Bartakova, Alena
    Michalova, Kveta
    Presl, Jiri
    Vlasak, Pavel
    Kostun, Jan
    Bouda, Jiri
    JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 2018, 38 (01) : 110 - 114
  • [27] Significance of site-specific prognosis of cancer stem cell marker CD44 in head and neck squamous-cell carcinoma
    Kokko, Linda-Lotta
    Hurme, Saija
    Maula, Sanna-Mari
    Alanen, Kalle
    Grenman, Reidar
    Kinnunen, Ilpo
    Ventela, Sami
    ORAL ONCOLOGY, 2011, 47 (06) : 510 - 516
  • [28] Role of CD44 as cancer stem cell marker in triple-negative breast cancer and its association with histological grade and angiogenesis
    Tomar, Reena
    Rakheja, Garima
    Verma, Nidhi
    Thakur, Shruti
    Khurana, Nita
    Ghuliani, Deepak
    INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY, 2023, 66 (02) : 258 - 263
  • [29] CD44 Is a Negative Cell Surface Marker for Pluripotent Stem Cell Identification during Human Fibroblast Reprogramming
    Quintanilla, Rene H., Jr.
    Asprer, Joanna S. T.
    Vaz, Candida
    Tanavde, Vivek
    Lakshmipathy, Uma
    PLOS ONE, 2014, 9 (01):
  • [30] EXPRESSION DISTRIBUTION OF CANCER STEM CELL MARKER, CD44 WITHIN MOLECULAR SUB TYPES OF BREAST CARCINOMA IN INDIAN PATIENTS
    Singh, K.
    Jain, M.
    Agarwal, K.
    Pathania, O. P.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2017, 27 : 671 - 671